Compare Abeona Therapeutics Inc (ABEO) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Quantum Computing Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Quantum Computing Inc trades at $8.73 (market cap $1.96B). The key difference: Quantum Computing Inc is far larger — about 5.3× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | QUBT | |
|---|---|---|
Market Cap | $373.32M | $1.96B |
Sector | Health | Technology |
52-Week High | $7.23 | $24.62 |
52-Week Low | $4.17 | $6.31 |
Enterprise Value | $228.22M | $977.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
QUBT trades at $9.37, up 3.54% today, but technical indicators signal a bearish trend with support at $9. The company shows minimal revenue of $682K in 2025 with a net loss of $18.67M, resulting in negative margins. Recent acquisitions and a potential $10M deal with Planck Dynamics highlight growth efforts, but cash burn remains high. Analyst consensus is bullish with a $24 price target, citing commercialization potential in quantum photonics.
The outlook hinges on QUBT's ability to scale revenue and manage cash burn amid intense quantum computing competition. While analyst optimism and policy tailwinds offer upside, high valuation multiples and persistent losses pose significant risks. Investors should weigh the long-term potential against near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
